{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:36:47Z","timestamp":1792784207611,"version":"4.5.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"the Emerging advanced technology joint research project from Shanghai Hospital Development Center","award":["SHDC12016103"],"award-info":[{"award-number":["SHDC12016103"]}],"id":[{"id":"https:\/\/ror.org\/02zrtve16","id-type":"ROR","asserted-by":"crossref"}]},{"name":"the Top-Level Clinical Discipline Project of Shanghai Pudong","award":["PWYgf2018-04"],"award-info":[{"award-number":["PWYgf2018-04"]}]},{"name":"the Key Projects of Shanghai Science and Technology Committee","award":["17411950800"],"award-info":[{"award-number":["17411950800"]}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81530019"],"award-info":[{"award-number":["81530019"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81770600"],"award-info":[{"award-number":["81770600"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1007\/s12072-020-10117-y","type":"journal-article","created":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T10:02:35Z","timestamp":1609495355000},"page":"155-165","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Low-dose rifaximin prevents complications and improves survival in patients with decompensated liver cirrhosis"],"prefix":"10.1007","volume":"15","author":[{"given":"Xin","family":"Zeng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-Qin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-Guang","family":"Xin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Bin","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Wei","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Zhi","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao-Tao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Juan","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-Mei","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zong-Li","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiong","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Ming","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi-Zhong","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Qing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nong-Hua","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7137-112X","authenticated-orcid":false,"given":"Wei-Fen","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,1]]},"reference":[{"key":"10117_CR1","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1016\/S0140-6736(14)60121-5","volume":"383","author":"EA Tsochatzis","year":"2014","unstructured":"Tsochatzis EA, Bosch J, Burroughs AK. Liver cirrhosis. Lancet. 2014;383:1749\u201361.","journal-title":"Lancet"},{"key":"10117_CR2","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1016\/j.jhep.2017.05.007","volume":"67","author":"R Wiest","year":"2017","unstructured":"Wiest R, Albillos A, Trauner M, et al. Targeting the gut-liver axis in liver disease. J Hepatol. 2017;67:1084\u2013103.","journal-title":"J Hepatol"},{"key":"10117_CR3","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1136\/gutjnl-2016-312729","volume":"65","author":"H Tilg","year":"2016","unstructured":"Tilg H, Cani PD, Mayer EA. Gut microbiome and liver diseases. Gut. 2016;65:2035\u201344.","journal-title":"Gut"},{"key":"10117_CR4","doi-asserted-by":"publisher","first-page":"12322","DOI":"10.3748\/wjg.v21.i43.12322","volume":"21","author":"FR Ponziani","year":"2015","unstructured":"Ponziani FR, Gerardi V, Pecere S, et al. Effect of rifaximin on gut microbiota composition in advanced liver disease and its complications. World J Gastroenterol. 2015;21:12322\u201333.","journal-title":"World J Gastroenterol"},{"key":"10117_CR5","doi-asserted-by":"publisher","first-page":"e195","DOI":"10.1038\/ctg.2016.52","volume":"7","author":"C Peleman","year":"2016","unstructured":"Peleman C, Camilleri M. Rifaximin, microbiota biology, and hepatic encephalopathy. Clin Transl Gastroenterol. 2016;7:e195.","journal-title":"Clin Transl Gastroenterol"},{"key":"10117_CR6","doi-asserted-by":"publisher","first-page":"e187","DOI":"10.1038\/ctg.2016.44","volume":"7","author":"DJ Kang","year":"2016","unstructured":"Kang DJ, Kakiyama G, Betrapally NS, et al. Rifaximin exerts beneficial effects independent of its ability to alter microbiota composition. Clin Transl Gastroenterol. 2016;7:e187.","journal-title":"Clin Transl Gastroenterol"},{"key":"10117_CR7","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1056\/NEJMoa0907893","volume":"362","author":"NM Bass","year":"2010","unstructured":"Bass NM, Mullen KD, Sanyal A, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med. 2010;362:1071\u201381.","journal-title":"N Engl J Med"},{"key":"10117_CR8","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1111\/apt.12803","volume":"40","author":"N Kimer","year":"2014","unstructured":"Kimer N, Krag A, M\u00f8ller S, et al. Systematic review with meta-analysis: the effects of rifaximin in hepatic encephalopathy. Aliment Pharmacol Ther. 2014;40:123\u201332.","journal-title":"Aliment Pharmacol Ther"},{"key":"10117_CR9","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1097\/MEG.0000000000000940","volume":"29","author":"F Kamal","year":"2017","unstructured":"Kamal F, Khan MA, Khan Z, et al. Rifaximin for the prevention of spontaneous bacterial peritonitis and hepatorenal syndrome in cirrhosis: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2017;29:1109\u201317.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10117_CR10","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1111\/apt.14275","volume":"46","author":"SH Kang","year":"2017","unstructured":"Kang SH, Lee YB, Lee JH, et al. Rifaximin treatment is associated with reduced risk of cirrhotic complications and prolonged overall survival in patients experiencing hepatic encephalopathy. Aliment Pharmacol Ther. 2017;46:845\u201355.","journal-title":"Aliment Pharmacol Ther"},{"key":"10117_CR11","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1038\/ajg.2013.219","volume":"108","author":"BC Sharma","year":"2013","unstructured":"Sharma BC, Sharma P, Lunia MK, et al. A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy. Am J Gastroenterol. 2013;108:1458\u201363.","journal-title":"Am J Gastroenterol"},{"key":"10117_CR12","doi-asserted-by":"publisher","first-page":"3621","DOI":"10.1007\/s10620-016-4313-0","volume":"61","author":"T Dong","year":"2016","unstructured":"Dong T, Aronsohn A, Gautham Reddy K, et al. Rifaximin decreases the incidence and severity of acute kidney injury and hepatorenal syndrome in cirrhosis. Dig Dis Sci. 2016;61:3621\u20136.","journal-title":"Dig Dis Sci"},{"key":"10117_CR13","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1097\/MEG.0000000000000967","volume":"29","author":"ES Ibrahim","year":"2017","unstructured":"Ibrahim ES, Alsebaey A, Zaghla H, et al. Long-term rifaximin therapy as a primary prevention of hepatorenal syndrome. Eur J Gastroenterol Hepatol. 2017;29:1247\u201350.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10117_CR14","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1111\/jgh.12970","volume":"30","author":"N Khokhar","year":"2015","unstructured":"Khokhar N, Qureshi MO, Ahmad S, et al. Comparison of once a day rifaximin to twice a day dosage in the prevention of recurrence of hepatic encephalopathy in patients with chronic liver disease. J Gastroenterol Hepatol. 2015;30:1420\u20132.","journal-title":"J Gastroenterol Hepatol"},{"key":"10117_CR15","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1111\/1751-2980.12294","volume":"16","author":"X Zeng","year":"2015","unstructured":"Zeng X, Tang XJ, Sheng X, et al. Does low-dose rifaximin ameliorate endotoxemia in patients with liver cirrhosis: a prospective study. J Dig Dis. 2015;16:665\u201374.","journal-title":"J Dig Dis"},{"key":"10117_CR16","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1002\/hep.27210","volume":"60","author":"H Vilstrup","year":"2014","unstructured":"Vilstrup H, Amodio P, Bajaj J, et al. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology. 2014;60:715\u201335.","journal-title":"Hepatology"},{"key":"10117_CR17","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1002\/hep.28906","volume":"65","author":"G Garcia-Tsao","year":"2017","unstructured":"Garcia-Tsao G, Abraldes JG, Berzigotti A, et al. Portal hypertensive bleeding in cirrhosis: risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. Hepatology. 2017;65:310\u201335.","journal-title":"Hepatology"},{"key":"10117_CR18","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1136\/gutjnl-2014-308874","volume":"64","author":"P Angeli","year":"2015","unstructured":"Angeli P, Gines P, Wong F, et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. Gut. 2015;64:531\u20137.","journal-title":"Gut"},{"key":"10117_CR19","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1007\/s00535-016-1216-y","volume":"51","author":"H Fukui","year":"2016","unstructured":"Fukui H, Saito H, Ueno Y, et al. Evidence-based clinical practice guidelines for liver cirrhosis 2015. J Gastroenterol. 2016;51:629\u201350.","journal-title":"J Gastroenterol"},{"key":"10117_CR20","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1111\/jgh.12070","volume":"28","author":"J Vlachogiannakos","year":"2013","unstructured":"Vlachogiannakos J, Viazis N, Vasianopoulou P, et al. Long-term administration of rifaximin improves the prognosis of patients with decompensated alcoholic cirrhosis. J Gastroenterol Hepatol. 2013;28:450\u20135.","journal-title":"J Gastroenterol Hepatol"},{"key":"10117_CR21","doi-asserted-by":"publisher","first-page":"175628481880030","DOI":"10.1177\/1756284818800307","volume":"11","author":"SL Flamm","year":"2018","unstructured":"Flamm SL, Mullen KD, Heimanson Z, et al. Rifaximin has the potential to prevent complications of cirrhosis. Therap Adv Gastroenterol. 2018;11:1756284818800307.","journal-title":"Therap Adv Gastroenterol"},{"key":"10117_CR22","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1111\/apt.12993","volume":"41","author":"JS Bajaj","year":"2015","unstructured":"Bajaj JS, Barrett AC, Bortey E, et al. Prolonged remission from hepatic encephalopathy with rifaximin: results of a placebo crossover analysis. Aliment Pharmacol Ther. 2015;41:39\u201345.","journal-title":"Aliment Pharmacol Ther"},{"key":"10117_CR23","doi-asserted-by":"publisher","first-page":"115","DOI":"10.5604\/16652681.1226822","volume":"16","author":"O Goyal","year":"2017","unstructured":"Goyal O, Sidhu SS, Kishore H. Minimal hepatic encephalopathy in cirrhosis- how long to treat? Ann Hepatol. 2017;16:115\u201322.","journal-title":"Ann Hepatol"},{"key":"10117_CR24","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1111\/liv.12921","volume":"36","author":"SS Sidhu","year":"2016","unstructured":"Sidhu SS, Goyal O, Parker RA, et al. Rifaximin vs. lactulose in treatment of minimal hepatic encephalopathy. Liver Int. 2016;36:378\u201385.","journal-title":"Liver Int"},{"key":"10117_CR25","doi-asserted-by":"publisher","first-page":"702","DOI":"10.5009\/gnl16478","volume":"11","author":"YL Lim","year":"2017","unstructured":"Lim YL, Kim MY, Jang YO, et al. Rifaximin and propranolol combination therapy is more effective than propranolol monotherapy for the reduction of portal pressure: an open randomized controlled pilot study. Gut Liver. 2017;11:702\u201310.","journal-title":"Gut Liver"},{"key":"10117_CR26","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/j.jhep.2012.06.011","volume":"57","author":"HL Zhang","year":"2012","unstructured":"Zhang HL, Yu LX, Yang W, et al. Profound impact of gut homeostasis on chemically-induced pro-tumorigenic inflammation and hepatocarcinogenesis in rats. J Hepatol. 2012;57:803\u201312.","journal-title":"J Hepatol"},{"key":"10117_CR27","doi-asserted-by":"publisher","first-page":"583","DOI":"10.2146\/ajhp110164","volume":"69","author":"LM Hynicka","year":"2012","unstructured":"Hynicka LM, Silva KN. Probable rifaximin-induced neutropenia. Am J Health Syst Pharm. 2012;69:583\u20136.","journal-title":"Am J Health Syst Pharm"},{"key":"10117_CR28","doi-asserted-by":"publisher","first-page":"874","DOI":"10.2146\/ajhp120137","volume":"70","author":"AS Patel","year":"2013","unstructured":"Patel AS, Supan EM, Ali SN. Toxic epidermal necrolysis associated with rifaximin. Am J Health Syst Pharm. 2013;70:874\u20136.","journal-title":"Am J Health Syst Pharm"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-020-10117-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12072-020-10117-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-020-10117-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,18]],"date-time":"2021-02-18T20:47:48Z","timestamp":1613681268000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12072-020-10117-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,1]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["10117"],"URL":"https:\/\/doi.org\/10.1007\/s12072-020-10117-y","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,1]]},"assertion":[{"value":"1 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Xin Zeng, Xia Sheng, Pei-Qin Wang, Hai-Guang Xin, Yi-Bin Guo,Yong Lin, Jia-Wei Zhong, Cheng-Zhi He, Jie Yin, Tao-Tao Liu, Wei-Juan Ma, Xiao Xiao, Pei-Mei Shi, Zong-Li Yuan, Ling Yang, Xiong Ma, Jian-Ming Xu, Xi-Zhong Shen, Chang-Qing Yang, Xuan Zhu, Nong-Hua Lv and Wei-Fen Xie declares that they have no conflict of interesting.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The study protocol was reviewed and approved by the institutional review board or ethics committee at each centre.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent was obtained from all patients.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}